US equity markets settled modestly weaker following a session absent any notable catalysts and as investors eye Thursday night’s AEST (10 June) consumer price inflation (CPI) report for May - Dow lost -126-points or -0.36% to 34,630.24, having climbed above its 7 May record closing high (34,777.76) earlier in the session. The broader S&P500 dipped -0.08%, with Materials (down -1.23%) leading seven of the eleven primary sectors lower. Real Estate (up +0.91%) was the leading primary sector performer. Biogen Inc surged 38.3% following news that the Food and Drug Administration (FDA) approved its Alzheimer’s disease drug aducanumab.
US equity markets settled modestly weaker following a session absent any notable catalysts and as investors eye Thursday night’s AEST (10 June) consumer price inflation (CPI) report for May - Dow lost -126-points or -0.36% to 34,630.24, having climbed above its 7 May record closing high (34,777.76) earlier in the session. The broader S&P500 dipped -0.08%, with Materials (down -1.23%) leading seven of the eleven primary sectors lower. Real Estate (up +0.91%) was the leading primary sector performer. Biogen Inc surged 38.3% following news that the Food and Drug Administration (FDA) approved its Alzheimer’s disease drug aducanumab.
read more
read less
